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ABBREVIATIONS 
Ab   antibody 
Itgb3   integrin 3  
BM   Bone marrow 
BMMNC  bone marrow mononuclear cells 
CB   cord blood 
DMSO   Dimethyl Sulphoxide 
EC   endothelial cell 
ECM   Extracellular matrix 
EGF   epidermal growth factor 
EGFL7  epidermal growth factor–like domain 7 
ETP   early thymic progenitor 
FBS   fetal bovine serum   
Flt3   FMS-like tyrosine kinase 3 
FN   fibronectin 
HSPCs   hematopoietic stem and progenitor cells 
HSC   hematopoietic stem cells 
HUVEC  Human Umbilical Vein Endothelial Cells 
IL   Interleukin 
KD   knockdown 
KitL     Kit ligand 
KSL    c-Kit+ Sca-1+ Lin−  
miRNA   micro RNA 
DLL1   Delta-like-1   
P/S   penicillin/streptomycin 
qPCR   quantitative polymerase chain reaction 
Rec.   recombinant 
RT   room temperature 
VEGF   vascular endothelial growth factor 
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Abstract 
Endothelial cells (ECs) and their growth factors are required for tissue regeneration, cancer 
progression, and stem cell maintenance. How these angiogenic factors modulate hematopoietic stem 
cell (HSC) fate is widely unknown. Epidermal growth factor–like domain 7 (Egfl7) is released by 
endothelium and deposited into the matrix. Here, I hypothesized that Egfl7 alters Notch signaling, 
thereby fine-tuning early progenitor fate dependent on the niche requirements. I demonstrate that ECs, 
and early stem and progenitor cells in the thymus (early thymic progenitors (ETPs) express Egfl7 
especially during tissue regeneration.  
Egfl7 expands ETPs and enhances their self-renewal capacity by activating Notch signaling and Flt3 
signaling. Egfl7 enhances ETP expanson by inducing Flt3 receptor expression and signaling. 
My results highlight the impact of the ECM-bound molecule Egfl7 on the regulation of ETPC fate by 
fine-tuning Notch and stem cell-active cytokine signaling pathways. 
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Introduction 
I. The angiogenic factor Egfl7 
Epidermal growth factor–like domain 7 (Egfl7, also known as vascular endothelial statin - 
VE-statin) is expressed in the endothelium during embryogenesis and during cancer growth. 
The mouse and human Egfl7 genes are located on chromosome 2 and 9, respectively (Fitch et 
al., 2004). The mouse gene spans 11.5 kb and consists of 11 exons (Soncin et al., 2003) with 
a micro RNA (miRNA), miR126, located between exons 7 and 8 (Fish et al., 2008; Kuhnert 
et al., 2008; Wang et al., 2008). The Egfl7 protein (29 kDa) is composed of several putative 
domains: a cleavable signal peptide at the N-terminal end, an EMI domain, found on 
extracellular matrix (ECM) proteins (Doliana et al., 2000), two epidermal growth factor 
(EGF)-like domains a leucine and valine rich C-terminal region. The Eglf7 protein is secreted 
from endothelial cells (ECs) and is deposited in the ECM perivascular. Overexpression 
of Egfl7 in mice results in abnormal patterning and remodeling of blood vessels (Nichol et al., 
2010). Tie2-Egfl7 transgenic mice overexpressing endothelial Egfl7 mRNA, without altering 
miR126 levels, exhibit partial embryonic lethality, which is accompanied by hemorrhaging 
and abnormal vascular patterning. Antibodies targeting Egfl7 prevented tumor 
neoangiogenesis by targeting Itgb3 expressing tumor ECs (Johnson et al., 2013; Parker et al., 
2004). 
The first EGF-like domain of Egfl7 has a region similar to the Delta/Serrate/Lag-2 domain 
found in ligands of the Notch receptors family (Fleming, 1998), the second EGF-like domain 
is predicted to bind Ca2+. Egfl7 was shown to antagonize Notch receptor/ligand interaction by 
binding to the receptor or its corresponding ligand on neuronal stem cells (Durrans and 
Stuhlmann, 2010; Schmidt et al., 2009).  
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Egfl7 or miR126 change the cellular behavior of cancer niche cells like EC, mesenchymal 
stem cells, and fibroblasts (Yang et al., 2016; Zhang et al., 2013). miR-126/miR-126* inhibit 
stromal cell-derived factor-1 alpha (Sdf-1α) expression suppressing mesenchymal stem cell 
recruitment by lung cancer cells in a mouse xenograft model (Zhang et al., 2013). mir-126* is 
the complementary strand to mir-126 which forms once the double stranded pri-miRNA is 
cleaved and the two strands denature, separating. mir-126* is less abundantly found in 
organisms than mir-126 and fewer roles in regulating gene expression have been identified.  
miR-126/miR-126* expression is downregulated in cancer cells by promoter methylation of 
their host gene Egfl7.  
GATA transcription factors can regulate gene expression in hematopoietic cells. 
The Egfl7 promoter also contains a GATA-2 consensus binding site (Le Bras et al., 2010), 
suggesting that Egfl7 could play a role in hematopoiesis. miR-126 knockdown (KD) in 
normal hematopoietic stem/progenitor cells (HSPCs) was reported to expand long-term HSCs 
by controlling multiple targets within the PI3K/AKT/GSK3β pathway in HSC/early 
progenitors (Lechman et al., 2012). During malignant hematopoiesis, like in acute myeloid 
leukemia (AML), miR-126 likely functions as an oncogene (de Leeuw et al., 2014; Li et al., 
2008) (Dorrance et al., 2015). However, miR-126 function seems to 2-faceted in leukemia 
where it either can promote or suppress progression of leukemic growth (Li et al., 2015).  
During my PhD studies, I examined the role of Egfl7 for normal hematopoietic stem and 
progenitor cell (HSPC) development.  
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II. Hematopoiesis 
Within the hematopoietic system, only HSCs possess the ability of both multipotency and 
self-renewal (Seita and Weissman, 2010). Multipotency is the ability to differentiate into all 
functional blood cells. Self-renewal is the ability to give rise to HSC itself without 
differentiation. Since mature blood cells are predominantly short-lived, HSCs continuously 
provide more differentiated progenitors while properly maintaining the HSC pool size 
throughout life by precisely balancing self-renewal and differentiation (Figure 0). But signals 
that regulate this balance of self-renewal and differentiation are not well defined. 
 
Figure 0. Impaired proliferation of murine Egfl7 knockdown KSL/progenitors 
During hematopoiesis, long-term HSC (LT-HSC) can respond to extracellular singals and 
differentiate into cells of the erythroid, lymphoid, and myeloid lineages.  
Although several markers have been used to identify human HSCs, CD34 is most commonly 
used for clinical use and the enrichment of human HSCs. HSCs from adult mouse bone 
marrow (BM) are c-Kit+ Sca-1+ Lin− (KSL) cells and show low or no expression for CD34. 
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These CD34-KSL cells show myelolymphoid long-term reconstitution in lethally irradiated 
recipients after a single cell transplant (Osawa et al., 1996).  
The low number of HSC in the adult BM hinders their use in the clinic. HSCs are rare with 
estimated frequencies of 1 in 10,000 BM cells and 1 in every 100,000 blood cells, suggesting 
a limiting number of true niches. A small pool of HSCs exists in the BM during adulthood in 
a quiescent state. This process is tightly controlled by a specific microenvironment, the so 
called BM niche that consists of the ECM and a plethora of stromal cells and non-
hematopoietic cells like ECs, osteoblasts and fibroblasts (Morrison and Scadden, 2014). A 
crosstalk of tissue-specific stem cells and their progenitors and ECs has been reported in stem 
cell niches harboring neuronal (Delgado et al., 2014; Shen et al., 2004), mesenchymal 
(Dhahri et al., 2016), or HSCs (Poulos et al., 2015).  
The niche cell composition dictates HSC numbers as shown e.g. in genetically engineered 
mice with increases in osteoblast numbers that led to elevated HSC numbers without changes 
in committed progenitor populations (Zhang et al., 2003).  ECs are another niche cell type 
important for HSC maintenance. Others and I have demonstrated that HSC can be found in 
close vicinity to ECs, especially after myelosuppression (Heissig et al., 2002), and that EC-
derived growth factors like vascular endothelial growth factor (VEGF-A), placental growth 
factor or Kit ligand (KitL, also known as stem cell factor) can enhance hematopoiesis 
(Avecilla et al., 2004; Hattori et al., 2002).  
HSCs proliferate and differentiate following hematological stress like bleeding, irradiation or 
chemotherapy in order to regenerate the blood cell pool. In the BM HSCs are anchored 
through cell-matrix adhesion and maintained by growth factors. A few growth factor 
receptors/ligands have been shown to play essential roles in HSC function, namely KitL/c-Kit, 
TPO/c-Mpl, and FMS-like tyrosine kinase 3 (Flt3).  Investigations of two mast cell-deficient 
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spontaneous mutant mouse strains, the W strain (Russell, 1949), and the Sl strain (Murphy et 
al., 1992), lead to the concept that the W locus was critical for HSCs while the Sl locus was 
important for signals from HSC niche cells (Mayer and Green, 1968; Russell and Bernstein, 
1968). In 1990, the critical gene in the W locus, the cytokine receptor-tyrosine kinase c-Kit 
was identified (Nocka et al., 1989). At approximately the same time, the important gene in 
the Sl locus was shown to encode KitL or Stem Cell Factor (Zsebo et al., 1990). 
Another important stem cell active cytokine receptor is FMS-like tyrosine kinase 3 (Flt3), 
which is expressed on approximately 60% of KSL cells. KSL Flt3+ cells rapidly and 
efficiently reconstituted B and T lymphopoiesis, whereby myeloid reconstitution was short 
term. Activation of Flt3 failed to support survival of HSC. 
Notch signaling is an important cell-cell communication system. The receptor is normally 
triggered via direct cell-to-cell contact, in which the transmembrane proteins of the cells in 
direct contact form the ligands that bind the Notch receptor. Notch signaling appears to 
inhibit differentiation programs that accompany Wnt-induced proliferation (Duncan et al., 
2005). However, genetic ablation studies suggest that at least some aspects of these pathways 
may be dispensable for in vivo HSC function (Duncan et al., 2005).  
Although HSC fate is dictated by external signals from the microenvironment through cell-
cell and cell-matrix interactions, factors to attune these cell-cell or cell-matrix interactions are 
not well defined. Active self-renewal and differentiation of HSCs is probably more likely to 
happen in the vascular niche, and was shown to be partly mediated by Notch signaling 
(Butler et al., 2010). The EC-derived Egfl7 is a promiscuous molecule. It can mediate 
integrin (cell-matrix) and Notch (cell-cell)-mediated signals.  
 
III. Thymogenesis 
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Impaired thymic function occurs in elderly people, after myelosuppression like chemotherapy 
or irradiation for cancer patients, and after myelosuppression used in preparation for HSC 
transplantation that leads to a malfunction of the immune system with an increased risk of 
infection, and ultimately death. Determining factors that control thymogenesis in the 
regenerating thymus will lead to a better understanding of the mechanisms underlying the 
limited organ regenerative capacity during aging, and after allogeneic hematopoietic stem cell 
transplantation. Strategies to improve thymic functions are therefore desirable. T cell 
reconstitution of the recipient immune system after allogeneic hematopoietic cell 
transplantation is largely dependent on replication of donor T cells infused with the BM 
(Weinberg et al., 2001), and can take several months to even years (de Koning et al., 2016).  
The thymic microenvironment is the cradle of T cell development. It represents a spectrum of 
developing T lymphoid cells, hematopoietic (mainly B cells, macrophages, and dendritic 
cells) and stromal cells like thymic epithelial cells, and thymic ECs. Myelosuppression after 
total body irradiation augments the release of other endothelial-derived factors like VEGF-A, 
and the Notch ligand Jagged-1 (Heissig et al., 2005; Hooper et al., 2009). Thymic ECs are 
resistant to damage as induced by chemotherapy, and sublethal total body irradiation. Yet, the 
role of thymic ECs and/or their released factors for steady state and stress-induced 
thymogenesis is unclear. The Flt3+ fraction of Lin− CD25− Kit+ early thymic progenitor (ETP) 
(Lin− CD25− Kit+ Flt3+) harbors canonical intrathymic T cell progenitors (Adolfsson et al., 
2005; Allman et al., 2003). Flt3 or Flt3 ligand (Flt3L) deficient mice display defects in very 
early T cell development (Adolfsson et al., 2001; Sitnicka et al., 2007). In addition, Flt3 has 
been shown to activate Stat3 and Stat5a signaling mediators. 
Notch signaling is essential for T lineage cell differentiation including T versus B and  
versus  lineage specification (for review see (Li and von Boehmer, 2011)). The c-Myc 
proto-oncogene has been identified as a critical direct downstream target of Notch in 
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leukemogenesis (Palomero et al., 2006). A stage-specific requirement for Notch signaling at 
the αβ and γδ T lineage bifurcation has been reported (Ciofani et al., 2006; Garbe et al., 2006). 
Notch receptor-ligand interactions are necessary for early T cell development. The earliest 
intrathymic T-cell precursors, which are characterized by high expression of c-Kit receptor 
and low expression of the interleukin 7 receptor alpha chain (IL7R), are found in the double-
negative DN1 thymocyte subset (CD4−CD8−CD25−CD44+) (Sambandam et al., 2005). Notch 
signaling is required not only for generation of the ETP population but also for transitions of 
ETP-to-DN2 and ETP-to-DN3 suggesting that Notch1 activation is needed continuously to 
promote survival or proliferation throughout the early stages of intrathymic T-cell 
development (Sambandam et al., 2005). 
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Genotype Phenotype 
miR126 -/- EC-restricted microRNA (miR-126) miR-126 enhances the 
proangiogenic actions of VEGF and FGF and promotes blood vessel 
formation by repressing Spred-1 expression (Wang et al., 2008) 
Egfl7transgenic Egfl7 and EC-specific NOTCH physically interact in vivo and strongly 
suggest that Egfl7 antagonizes Notch in both the postnatal retina and 
in primary ECs (Nichol et al., 2010) 
c-kit -/-  
(Kit-Kitw-v) 
Kit mice possess pleiotropic defects in pigment-forming cells, germ 
cells, RBC's and mast cells. In addition, they exhibit impaired 
resistance to parasitic infection and an intrinsic progenitor cell 
defect. KitW-v homozygotes resemble KitW homozygotes in color, 
anemia, and germ cells, but many of them survive to maturity (Huang 
et al., 1990) (Fleishman, 1996) 
FLT3-/- Mutants developed into healthy adults with normal mature 
hematopoietic populations. However, they possessed specific 
deficiencies in primitive B lymphoid progenitors. Bone marrow 
transplantation experiments revealed a further deficiency in T cell and 
myeloid reconstitution by mutant stem cells (Mackarehtschian et al., 
1995) 
Beta3 -/- Mice are viable at birth with bleeding diathesis due to a platelet defect, 
the murine homologue of Glanzmann’s thrombasthenia. Osteoclast 
functional defect in the bones of mutant mice were reported (Hodivala-
Dilke et al., 1999) 
Notch1-/- Competitive repopulation of lethally irradiated wild-type hosts with 
wild-type- and Notch1-deficient BM revealed a cell autonomous 
blockage in T cell development at an early stage, before expression of 
T cell lineage markers (Radtke et al., 1999). Notch1 activation 
increases hematopoietic stem cell self-renewal in vivo and favors 
lymphoid over myeloid lineage outcome(Stier et al., 2002) 
 
Table 1: Summary of genes important for this study and the murine knockout phenotype, 
with special focus on the hematopoietic phenotype. 
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Hypothesis 
Thymopoiesis allow for the generation mature lymphocytes both under steady state and 
following stress situations like ischemia, myelosuppression, or during cancer growth. ECs 
located e.g. in the stem cell niche release angiogenic factors that can regulate steady state and 
stress-induced thymogenesis. The angiogenic factor epidermal growth factor–like domain 7 
(Egfl7) is a promiscuous molecule, because it can bind to stem cell-associated receptors like 
the platelet-derived growth factor-beta receptor, Itgb3 and Notch1-4 receptors.   
Here, I hypothesized that Egfl7 dictates early progenitor fate by fine-tuning Notch signaling 
through its ability to bind to some receptor, thereby altering critical stem cell signaling 
pathways.  
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Material and Methods 
Experimental Animals and human cord blood samples 
C57BL/6 mice (6-8 weeks old) were purchased from SLC, Inc. (Shizuoka, Japan). Animal 
experiments were conducted in accordance with the guidelines and approval of the 
Institutional Animal Care and Usage Committee at the Institute of Medical Science, The 
University of Tokyo. 
 
In vivo manipulation of mice 
Groups of whole-body irradiated mice (6-8 wks old; 2 Gy using 137C) were given AdEgfl7 or 
AdNull in the tail vein. Thymic recovery was determined 3 days (d) after irradiation of the 
mice. At d 0, mice were irradiated with a single dose of 2 Gy. 
 
Overexpression of Egfl7 using adenoviral injections 
Adenoviral vectors expressing Egfl7 or containing no transgene were kindly provided by 
Matthias Friedrich and Dirk Dikic (Institute of Biochemistry II, Johann Wolfgang Goethe 
University School of Medicine) (Picuric et al., 2009; Schmidt et al., 2009). In brief, this 
replication-deficient adenovirus is based on adenovirus type 5, which lacks the EIA, E1B, 
and E3 regions of the virus and contains the SRa promoter, human Egfl7 cDNA, and SV40 
poly(A) signal sequences inserted into the El-deleted region. Null Adenovirus (AdNull, 
empty vector), contains the SRa promoter and SV40 poly(A) signal. Purified virus stocks 
were prepared through CsCl step gradient centrifugation as described (Kanegae et al., 1994). 
Mice were intravenously injected with 2 x 109 plaque-forming units of AdEgfl7 and AdNull 
in the tail vein. Mice were sacrificed on d3 for thymus collection or at indicated time points 
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for BM collection. Peripheral blood samples obtained were collected using heparin-coated 
capillaries. 
 
Blocking experiments in vivo 
AdEgfl7 or AdNull was co-injected with Flt3 inhibitor (Tandutinib) (30mg/kg) or PBS orally 
daily at d 0, 1, and 2. 
 
Flow cytometry and cell sorting 
Tissue preparation: Thymi were minced, and thymus single cell suspensions were blocked 
with 2% FBS, washed and stained. Murine BM cells were obtained after flushing femurs and 
tibiae.  
MACS sorting. BMMNCs were stained using a lineage cell depletion kit (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany). After running through 2 MACS columns (Miltenyi 
Biotec) more than 90% of the separated cells were lineage negative (Lin-) by FACS.  
For thymic EC isolation thymocytes were stained with CD45 and CD31 magnetic beads and 
isolated by MACS (Miltenyi Biotec). 
FACS sorting.  
Flow cytometry analysis and sorting were performed on a FACS Verse and Area (BD 
Biosciences) flow cytometers. Data were analyzed using the FlowJo software (Tree Star, 
Ashland, OR, USA).  
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Cell cultures 
Mouse stem cell and progenitor proliferation assay 
ETP Proliferation assay. 1 × 103 FACS sorted ETP cells per well were cultured in Dulbecco's 
modified Eagle's medium containing 20% FBS supplemented recombinant mouse Kit ligand 
(PeproTech, 50 ng/ml), mouse IL-7 (PeproTech, 50 ng/ml), mouse Flt3 ligand (PeproTech, 
50 ng/ml) with or without recombinant Egfl7 (Abnova, 300 ng/ml) at the start of the culture. 
The Flt3 inhibitor (Tandutinib, ChemScene) was added at a concentration of 25uM to 
indicated cultures. On d 3 of culture, cells were counted, and the percentage of ETP was 
determined using FACS.  
Some cultures were supplemented with inhibitory reagents: Inhibitors for Flt3 (Tandutinib, 
ChemScene; 25uM) were added at day 0. Cells after 5 days in culture were collected and 
either analyzed by FACS or samples were prepared for qPCR and Western Blot. 
 
Quantitative RT-PCR Analysis 
Total RNA was prepared from cell pellets using TRIzol Reagent (Ambion by Life 
Technologies, #15596018) according to the manufacturer's instructions. First-strand cDNA 
was synthesized from 0.2-2μg of total RNA using a High Capacity Reverse Transcriptase kit 
(Applied Biosystems). The cycle number for PCR was 40 for all samples using a qPCR 
machine Step One Plus (Applied Biosystems) with SYBR Premix Ex Taq II (x2) Tli RNaseH 
Plus (Takara, #RR820). Primer sequences are provided in Annex.  
 
Western blot analysis 
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Cultured HUVEC transfected with 30 MOI AdEgfl7 or AdNull were lysed with lysis buffer 
(Cell Signaling Technology). In some experiments BMMNCs were lysed. Protein crude was 
recovered by acetone. Cell lysates (2~50μg proteins) were applied on 10% acrylamide gel, 
transferred to PVDF membrane (Millipore, Immobilon), blocked, then stained overnight at 
4°C for Egfl7 (Santa Cruz Biotech, sc-34416), c-Kit (Santa Cruz Biotech, sc-5535), FAK 
(Merk Millipore, #07-832), Hes1 (Santa Cruz Biotech, sc-25392), ß-actin (Cell Signaling, 
#4967), p-ERK (Cell Signaling, #4370), p-AKT (Cell Signaling, #9271), Tyr747 (Santa Cruz 
Biotech, sc-20234), p-JAK-2 (Merk Millipore, #07-706), p-STAT3 (Cell Signaling, #9131), 
FLT3 (Proteintech, 21049-1-AP), and NICD (cleaved Notch1 (Val1744) (D3B8) rabbit mAb 
#4147, Cell signaling). Membranes were stained with secondary antibody conjugated with 
horseradish peroxidase (Nichirei, rabbit-HRP or goat-HRP), and developed with the ECL 
Plus detection system (Amersham Life Science, RPN2132) using image analyzer Image-
Quant LAS4000 (GE-healthcare). 
 
ELISA 
Flt3 ligand plasma levels were measured using commercially available ELISA kits (R&D 
Systems Inc., Minneapolis, MN) according to the manufacturer's protocol. 
 
Immunostaining 
Thymi were embedded in OCT compound (Sakura), and frozen. Tissue sections (5μm) were 
cut with an OM cryostat (HM500; Microm) and collected onto Superfrost/Plus slides (Fisher 
Scientific). For immunohistochemical staining of mouse thymus, 4% formaldehyde fixed 
cryo-sections were blocked with 5% BSA in PBS solution, and stained over night at 4°C with 
goat anti-Egfl7 (Santa Cruz Biotech, sc-34416), anti-Flt3 (proteintech, 21049-1-AP), and 
anti-CD31 (Santa Cruz Biotech, sc-28188). After two washing steps, tissue sections were 
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incubated for 1 hrs at RT with Alexa Fluor 488 rabbit anti-goat IgG, Alexa Fluor 488 donkey 
anti-rabbit IgG, Alexa Fluor 594 goat anti-rabbit IgG and Alexa Fluor 488 donkey anti-rabbit 
IgG, respectively. Sections were counterstained with DAPI. 
 
Statistical analysis 
Results are presented as means ±SEM. Statistical comparisons were based on Student’s t test 
or ANOVA with Tukey HSD posthoc tests using R program. P value level of <0.05 was 
considered significant.   
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Results 
VIII. Perivascular Egfl7 deposition in the irradiated thymus 
Egfl7 transcripts were found by qPCR in lymphoid organs like the thymus, and spleen 
(Figure 9A). High Egfl7 expression was detected on MACS-sorted CD45-CD31+ ECs, and 
FACS-sorted CD44+c-Kit+CD25- ETP (Figure 9A). Impaired thymic function after 
myelosuppressive irradiation or during aging can deplete the thymus of lymphoid cells and 
damage thymic stroma cells. Egfl7 mRNA was upregulated in thymi 3 d after sublethal 
irradiation with 2 Gy (Figure 9A). Immunoreactive Egfl7 was found perivascular in thymi of 
irradiated, but not in non-irradiated mice (Figure 9B). These data indicate that Egfl7 is 
expressed in a thymocyte subpopulation and thymic EC, and its expression is upregulated 
after sublethal irradiation. 
 
IX. Egfl7 augments early thymic progenitors and ECs 
To investigate Egfl7’s role for T cell development in vivo, C57/BL6 mice were injected 
intravenously AdEgfl7 or AdNull (Figure 9C). Egfl7 overexpression was confirmed in liver 
cell lysates from adenovirus-injected mice by Western blotting (Figure 9D). Next, I 
determined the thymic T cell differentiation that can be divided into discrete stages 
characterized by the expression pattern of CD4 and CD8. CD4 and CD8 double negative 
(DN) cells are the early T cell progenitors, that can differentiate into CD4 and CD double 
positive (DP) and then give rise to CD4 or CD8 single-positive (SP) cells. T cell 
differentiation in spleen and peripheral blood was unchanged (data not shown). While the 
frequency of CD4+ and CD8+ SP and DN increased, the percentage of DP decreased (Figure 
9F) in thymocytes retrieved from AdEgfl7-injected mice at d 3. This translated into a two-
fold decrease in thymic cellularity, a 50% reduction in thymus size and thymocyte cell 
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number in AdEgfl7 injected (data not shown). These results suggest that Egfl7 is a modulator 
of early T cell development. 
Figure 9. Egfl7 is upregulated after irradiation and expands immature thymic progenitors 
(A) Egfl7 expression as determined by qPCR (n=3/group) of total thymocytes from non-irradiated and 
mice irradiated with 2 Gy, splenocytes, FACS-sorted ETP based on CD45, CD44, c-Kit and CD25 
expression, and MACS-sorted CD45-CD31+ endothelial cells (ECs) (n=2). Transcript levels were 
normalized to -actin. Graphs represent averages from three to seven independently prepared 
templates. The data represent three independent experiments with similar results. (B) Thymus sections 
isolated from mice before (WT) and 3 d after irradiation were stained with antibodies against Egfl7 
(shown in green) and endothelial cell-associated CD31 (shown in red).  (C-F) Schematic 
representation of the experimental design: C57/BL6 mice were injected intravenously (i.v.) with 
AdEgfl7 or AdNull (no transgene) on d 0. (D) Egfl7 expression was determined in liver cell lysates by 
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Western blotting 3 d after injection. (E) Representative FACS blots of CD4 and CD8 stained 
thymocytes isolated from vector-treated and non-treated mice. (F) Frequency of CD4+ and CD8+ 
single positive (SP), double positive (DP), and CD8 and CD4 double negative (DN) thymocytes was 
assessed by FACS (n=6). Values are the mean ± SEM of duplicate data points. *p<0.05, ** p<0.01 for 
all experiments. 
 
 
X.  Egfl7 augments ETPs under steady state condition and after irradiation 
The increase in the DN fraction (Figure 10A and 10B) was due to an accumulation of DN1 
thymocytes (Figure 10B) that also harbors the most primate thymic progenitor ETP 
population (LinlowCD44+CD25-c-kit+), a fraction that was increased in thymocytes of 
AdEgfl7-treated mice (Figure 10C). 
To understand if Egfl7 upregulation after irradiation might have functional consequences for 
thymic regeneration, groups of irradiated mice were injected with AdEgfl7 or AdNull. Thymi 
retrieved from AdEgfl7-treated mice showed a 2.5-fold increase in ETPs around 2.5-fold 
after irradiation compared to AdNull controls (Figure 10D). I show increased CD31 
expression on EC after irradiation (Figure 10E). Similarly, an increase in Lin-c-Kit+CD31+ 
ECs was observed after Egfl7 overexpression in thymi isolated 3 d after irradiation (Figure 
10F). These data indicate that forced overexpression of Egfl7 expanded ETP and thymic ECs 
even after irradiation.  
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Figure 10. Egfl7 expands early thymic progenitors and thymic ECs after irradiation 
(A-C) Thymocytes were isolated from nonirradiated (A-C) or irradiated (D-F) mice injected with 
AdEgfl7 or AdNull. (A-B) DN thymocytes were characterized using CD44 and CD25 as 
demonstrated in the representative gating schemes (A): DN1, CD25−CD44+; DN2, CD25+CD44+; 
DN3, CD25+CD44−; DN4, CD25−CD44−), and their percentage in each subpopulation is shown (B) 
(n=9).  (C) Frequency of CD44+c-Kit+CD25- ETPs (left panel; n=9). Right panel show representative 
FACS plots of CD25 and c-Kit expression of pregated CD44+ thymocytes. (D-F) 2 Gy irradiated mice 
were injected with AdEgfl7 or AdNull i.v. on d 0 (n=6/group). Thymi were analyzed 3 d after 
irradiation. (D) Intrathymic frequency of ETP is given (left panel; n=9). Right panel shows 
representative FACS plots of CD25 and c-Kit expression of pregated CD44+ thymocytes.  (E) 
Representative images of immunoreactive CD31 on thymic tissue sections in non-irradiated (WT) and 
irradiated mice (2Gy). (F) Representative FACS blot showing c-Kit and CD31 expression of pregated 
lin- thymocytes isolated from control and vector-injected mice at day 3 (left panel). Frequency of 
thymic Lin-c-Kit+CD31+ ECs isolated from non-irradiated and irradiated mice (n=5/group). Values are 
mean ± SEM. All data are representative of at least two independent experiments. *p<0.05, ** p<0.01 
for all experiments. 
 
 
XI.  Egfl7 upregulates Flt3 receptor on ECs  
Because Flt3 receptor signaling is important for ETP maintenance during steady-state 
thymopoiesis (Kenins et al., 2010), I investigated whether Egfl7 mediates cellular changes in 
the thymus by altering the Flt3/Flt3-ligand (Flt3L) pathway. Thymic tissues retrieved from 
mice after AdEgfl7 injection showed high Egfl7, Flt3 and Flt3L (Figure 11A-C), but low 
Hes1 expression by qPCR (Figure 11D). Egfl7 and Flt3 up- and Hes1 down-regulation was 
confirmed by Western blotting in AdEgfl7 infected human umbilical vein EC (HUVEC) 
(Figure 11E). Egfl7 overexpression led to the phosphorylation of Flt3 downstream signaling 
molecules of receptor tyrosine kinases like including AKT, STAT-3 and ERK1/2 in HUVEC 
(Figure 11E). Because Flt3L is produced by ECs (Solanilla et al., 2000), I reasoned that Flt3L 
plasma levels also might be elevated, which indeed was the case in AdEgfl7-treated mice 
(Figure 11F). Immunoreactive Flt3 was higher in irradiated thymic tissues (Figure 11H). Flt3 
expression increased in thymic ETP, and ECs derived from AdEgfl7 treated or irradiated 
mice as determined by FACS (Figure 11H). These data demonstrate that Egfl7 upregulates 
Flt3 expression on ETP, and thymic ECs, and enhances the release of Flt3L from ECs (Figure 
11I). 
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Figure 11. Enhanced Flt3-Flt3 ligand signaling after Egfl7 overexpression 
(A-D) Egfl7 (A), Flt3 ligand (C) Flt3, and (F) Hes-1 mRNA induction was measured by qPCR in 
thymocytes isolated from AdNull and AdEgfl7 or untreated animals at d 3. (E) Adenovirus-treated 
HUVEC cells were collected after 24 h. Proteins were immunoblotted with the indicated antibodies. 
Representative blots are shown (n=2). (F) Flt3 ligand was assayed in plasma of mice with or without 
total body irradiation that were cotreated with AdEgfl7 by ELISA (n=5/group). (G) Representative 
images of immunoreactive Flt3 of thymi from non-irradiated (WT) and irradiated mice. (H) Flt3 
expression in indicated thymic cell populations isolated from AdEgfl7 treated mice with or without 
irradiation in vivo as determined by FACS. Upper panel: FACS histograms showing Flt3 expression 
on CD44+c-Kit+CD25- ETPs, and Lin-c-Kit+ CD31+ EC. One representative of 3 experiments is shown. 
Lower panel: % expression of Flt3 on pregated ETP, and EC populations (n=6).  (I) The depiction is a 
working model that implicates how Egfl7 might alter Flt3 expression. Egfl7-mediated Notch signaling 
blockade lead to Hes1 down-regulation leading to the induction of Flt3 expression. Values are mean ± 
SEM. *p<0.05, ** p<0.01 for all experiments. 
 
XII.  Egfl7 expands ETP and ECs by activating Flt3 signaling 
Finally, to establish whether Flt3 signaling is critical for the observed ETP and thymic EC 
expansion, a Flt3 inhibitor was exploited. Flt3 inhibition prevented Egfl7-mediated ETP and 
thymic EC expansion in vivo (Figure 12A, 12B). Finally, I asked whether rec. Egfl7 was able 
to expand ETP in vitro. The addition of Egfl7 to cytokine-supplemented cultures readily 
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expanded ETP in stroma-free cultures after 3 d, a process that could be blocked in the 
presence of an Flt3 inhibitor (Figure 12E). Egfl7 enhances Flt3 signaling (Figure 12F). I 
propose that Egfl7 enhances the lympho-stromal cross talk that might have important 
implication for thymus organogenesis and regeneration that is necessary to maintain the 
thymic progenitor pool. In summary, the angiogenic factors like Egfl7 provide key molecular 
drivers enforcing thymus progenitor generation and thereby directly link endothelial biology 
to the production of T cell-based adaptive immunity. 
 
Figure 12: Pharmacological inhibition of Flt3 prevented Egfl7-mediated ETP and EC expansion 
(A-B) C57Bl/6 mice were injected with adenovirus expressing Egfl7 or no transgene and cotreated 
daily with Flt3 inhibitor. The percentage of CD44+c-Kit+CD25- ETP (A), and Lin-c-Kit+CD31+ EC (B) 
was determined (n=5/group). (C) FACS-isolated CD44+c-Kit+CD25- ETP were cultured for 3 d in the 
mentioned cytokines in the presence or absence of rec. Egfl7 (n=5/group). (D) Model of Egfl7 effects 
in the thymic niche. Egfl7 induced in cells e.g. after irradiation blocks intracellular Notch signaling in 
target cells leading to expansion of ETP and EC through upregulation of Flt3 receptor on target cells 
and the release of Flt3 ligand. Values are mean ± SEM. *p<0.05, ** p<0.01 for all experiments. 
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Discussion 
EC-derived (angiocrine) factors modulate stem cell fate in the vascular stem cell niche 
(Avecilla et al., 2004; Butler et al., 2010; Heissig et al., 2002; Kiel and Morrison, 2006).  
Egfl7 blocked Notch signaling with down-regulation of Hes1 expression that induced Flt3 
signaling on ETPs. Flt3 receptor expression was induced on ETPs after Egfl7 treatment 
(Salama et al., 2017), and ECs. Flt3/FL signaling is critical for T cell progenitor expansion in 
vitro (Moore and Zlotnik, 1997) and in vivo (Mackarehtschian et al., 1995). In accordance 
with my data it was reported that Hes1 binds to the promoter region of the Flt3 gene and 
enhances the promoter activity of Flt3 in leukemic cells (Kato et al., 2015).  Pharmacological 
Flt3 blockade abolished Egfl7-mediated ETP proliferation. In support for a role of Egfl7 to 
block the Notch pathway, I observed in the thymus expansion of early thymocytes at the DN1 
stage, and a differentiation block. This phenotype is similar to the one reported for mice with 
loss of Notch signaling. 
The number of naive T cells decreases considerably with age, which is partly linked to the 
involution of the thymus (Linton and Dorshkind, 2004).  
Interestingly, Egfl7 is highly expressed in fetal and prenatal ETPs and downregulated in ETPs 
from older mice (Berent-Maoz et al., 2015). In ETP, Egfl7 expression was associated with a 
“young progenitor cell phenotype” that correlated with the expression of the high mobility 
group A2 protein, a factor shown to regulate HSC self-renewal potential (Copley et al., 2013). 
I indeed showed that Hes-1 in thymocytes fter Egfl7 overexpression led to a dramatic 
increase in Hes1, leading to increased detection of NICD, a processed active form of Notch1. 
While in my tested total BMMNCs Hes1 lead to increases in NICD, Hes1 was shown to act 
as an inhibitor rather than an effector of Notch signaling in embryonic stem cells that delays 
embryonic stem cell differentiation and promotes preference for the mesoderm rather then 
neuronal fate (Kobayashi and Kageyama, 2010).  
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I set forward the idea that Egfl7 downregulation during aging leads to Notch activation, 
causing the decline of lymphoid progenitor fitness that can lead to aging-associated 
leukemogenesis (Henry et al., 2010).  
My findings might also have important implications for blood-borne and solid cancer 
treatment. Internal tandem duplication mutations within FLT3 render the receptor 
constitutively active, driving proliferation and survival in leukemic blasts occurring in around 
25% of AML (Chu et al., 2012) it will be important to understand the regulation of Egfl7 in 
AML cells. FLT3 inhibitors together with conventional chemotherapy have shown good 
treatment outcome in patients with FLT3-positive AML (Hassanein et al., 2016). 
 In AML cells Syk was shown to be a critical regulator of FLT3 (Puissant et al., 2014). 
Clustering of Itgb3 promotes transphosphorylation in the kinase domain of Src, which is 
followed by the recruitment and phosphorylation of Syk, which can occur in concert with 
signaling downstream from growth-factor receptors. Further studies will be important to 
understand the involvement of Egfl7 for these signaling pathways. 
 
Conclusion 
Collectively, I identify the ECM-bound protein Egfl7 as a critical factor that controls the 
thymic niche by fine-tuning Notch signaling and high-jacking various critical stem cell active 
cytokine receptors/tyrosine kinases that can promote thymus regeneration.  
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Annex 
  Primer sequences 
Table 1. Primer list for quantitative polymerase chain 
reaction assay. 
 
gene name  Forward primer sequence  Reverse primer sequence 
h-actin 5'-GACGACATGGAGAAAATCTG-3' 5'-AGGTCTCAAACATGATCTGG-3' 
hEgfl7 5'-TGTAGCCAGGATGAGCAGTG-3'  5'-GCGGAGGAGAATCAGTCATC-3' 
mB-actin 5'-CCAACCGTGAAAAGATGACC-3' 5'-ACCAGAGGCATACAGGGACA-3' 
mEgfl7 5'-GCGCTGCCTGTCTAAGGA-3' 5'-CCTCTCTCGCCATGCTGT-3' 
mHes1 5'-GTGGGTCCTAACGCAGTGTC-3' 5'-ACAAAGGCGCAATCCAATATG-3' 
mFLT3 5'-GCCTCATTTCCTTGTGAACAG-3' 5'-GCTTGTTCTTATGATCGCAAAAT-3' 
 
 
  
29 
 
Acknowledgments 
 
Foremost, I would like to thank my supervisor Prof. Beate Heissig for her inspiration, support 
and guidance throughout my PhD journey. She has been excited and interested in my work. 
She has always been there to discuss and advise me. I am very thankful for her enthusiasm, 
patience, motivation, passion and deep knowledge in Stem Cell Biology and Regenerative 
Medicine, making her a great supervisor. I could learn and being high skillful researcher 
ready to start a new journey in the field of Stem cells and cancer biology field. 
 
I would like to thank Dr. Koichi Hattori for his support and guidance. He has a special sense 
for science and taught me how to build up knowledge. Beside that, he always took care of me 
when I had health or physical issue in the hospital.  
 
Thanks for present and past members of the Stem Cell Dynamics Lab for sharing their 
knowledge and providing me with comments and suggestion, which made my project to be 
great.  
 
I would like to extend my appreciation for Prof. Hiromitsu Nakauchi for giving me the 
chance to be a member of the Stem cell biology and Regenerative medicine center. I am 
thankful for him and for his unlimited support. Many thanks goes also for all of the members 
of the centers for being patience and giving me time from their busy and time. 
 
For the non-scientific part of my PhD, I am very grateful for meeting a lot of nice people who 
made me feel I am in my second home. Firstly, my appreciation and gratefulness goes to my 
hosting family in Japan, my father, Kouichi Yamamoto and Mom, Mitsue Yamamoto for their 
patience, help and support during all of my staying here in Japan, I was like there real son. 
Second, I would like to thank all my friends whom I met here in Japan. They were always 
there when I was in need for help. I spend such a great time together, leaving behind good 
memories that will last forever with all of us. 
 
My deep thanks for the Japan government representing by MEXT for giving me the chance to 
do my research here in Japan by providing me with a scholarship that covered every things 
related to my study. Without their kind support and trust my research was difficult to do. I 
wish this country and the people of Japan to always have all of the best and prosperity. 
 
Finally and not finally, I dedicate this thesis to my beloved family, for their constant support 
and unconditional love. They were patience during my absence from the home for 6 years. 
They missed me all of the time, but never make me felt I am absent.  
 
 
 
  
30 
 
References 
Adolfsson, J., Borge, O.J., Bryder, D., Theilgaard-Mönch, K., Åstrand-Grundström, I., Sitnicka, E., 
Sasaki, Y., and Jacobsen, S.E.W. (2001). Upregulation of Flt3 Expression within the Bone Marrow 
Lin−Sca1+c-kit+ Stem Cell Compartment Is Accompanied by Loss of Self-Renewal Capacity. Immunity 
15, 659-669. 
Adolfsson, J., Mansson, R., Buza-Vidas, N., Hultquist, A., Liuba, K., Jensen, C.T., Bryder, D., Yang, L., 
Borge, O.J., Thoren, L.A., et al. (2005). Identification of Flt3+ lympho-myeloid stem cells lacking 
erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 121, 
295-306. 
Allman, D., Sambandam, A., Kim, S., Miller, J.P., Pagan, A., Well, D., Meraz, A., and Bhandoola, A. 
(2003). Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 4, 168-174. 
Avecilla, S.T., Hattori, K., Heissig, B., Tejada, R., Liao, F., Shido, K., Jin, D.K., Dias, S., Zhang, F., 
Hartman, T.E., et al. (2004). Chemokine-mediated interaction of hematopoietic progenitors with the 
bone marrow vascular niche is required for thrombopoiesis. Nature medicine 10, 64-71 Epub 2003 
Dec 2021. 
Berent-Maoz, B., Montecino-Rodriguez, E., Fice, M., Casero, D., Seet, C.S., Crooks, G.M., Lowry, W., 
and Dorshkind, K. (2015). The Expansion of Thymopoiesis in Neonatal Mice Is Dependent on 
Expression of High Mobility Group A 2 Protein (Hmga2). PloS one 10, e0125414. 
Butler, J.M., Kobayashi, H., and Rafii, S. (2010). Instructive role of the vascular niche in promoting 
tumour growth and tissue repair by angiocrine factors. Nature reviews Cancer 10, 138-146. 
Chu, S.H., Heiser, D., Li, L., Kaplan, I., Collector, M., Huso, D., Sharkis, S.J., Civin, C., and Small, D. 
(2012). FLT3-ITD Knock-in Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to 
Myeloproliferative Neoplasm. Cell stem cell 11, 346-358. 
Ciofani, M., Knowles, G.C., Wiest, D.L., von Boehmer, H., and Zúñiga-Pflücker, J.C. (2006). Stage-
Specific and Differential Notch Dependency at the αβ and γδ T Lineage Bifurcation. Immunity 25, 
105-116. 
Copley, M.R., Babovic, S., Benz, C., Knapp, D.J.H.F., Beer, P.A., Kent, D.G., Wohrer, S., Treloar, D.Q., 
Day, C., Rowe, K., et al. (2013). The Lin28b–let-7–Hmga2 axis determines the higher self-renewal 
potential of fetal haematopoietic stem cells. Nature cell biology 15, 916-925. 
de Koning, C., Nierkens, S., and Boelens, J.J. (2016). Strategies before, during, and after 
hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood 128, 2607. 
de Leeuw, D.C., Denkers, F., Olthof, M.C., Rutten, A.P., Pouwels, W., Schuurhuis, G.J., Ossenkoppele, 
G.J., and Smit, L. (2014). Attenuation of microRNA-126 expression that drives CD34+38- 
stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer research 74, 
2094-2105. 
Delgado, A.C., Ferron, S.R., Vicente, D., Porlan, E., Perez-Villalba, A., Trujillo, C.M., D'Ocon, P., and 
Farinas, I. (2014). Endothelial NT-3 delivered by vasculature and CSF promotes quiescence of 
subependymal neural stem cells through nitric oxide induction. Neuron 83, 572-585. 
Dhahri, D., Sato-Kusubata, K., Ohki-Koizumi, M., Nishida, C., Tashiro, Y., Munakata, S., Shimazu, H., 
Salama, Y., Eiamboonsert, S., Nakauchi, H., et al. (2016). Fibrinolytic crosstalk with endothelial cells 
expands murine mesenchymal stromal cells. Blood 128, 1063-1075. 
Doliana, R., Bot, S., Bonaldo, P., and Colombatti, A. (2000). EMI, a novel cysteine-rich domain of 
EMILINs and other extracellular proteins, interacts with the gC1q domains and participates in 
multimerization. FEBS letters 484, 164-168. 
Dorrance, A.M., Neviani, P., Ferenchak, G.J., Huang, X., Nicolet, D., Maharry, K.S., Ozer, H.G., 
Hoellarbauer, P., Khalife, J., Hill, E.B., et al. (2015). Targeting leukemia stem cells in vivo with 
antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29, 2143-2153. 
Duncan, A.W., Rattis, F.M., DiMascio, L.N., Congdon, K.L., Pazianos, G., Zhao, C., Yoon, K., Cook, J.M., 
Willert, K., Gaiano, N., et al. (2005). Integration of Notch and Wnt signaling in hematopoietic stem 
cell maintenance. Nat Immunol 6, 314-322. 
31 
 
Durrans, A., and Stuhlmann, H. (2010). A role for Egfl7 during endothelial organization in the 
embryoid body model system. J Angiogenes Res 2, 4. 
Fish, J.E., Santoro, M.M., Morton, S.U., Yu, S., Yeh, R.F., Wythe, J.D., Ivey, K.N., Bruneau, B.G., 
Stainier, D.Y., and Srivastava, D. (2008). miR-126 regulates angiogenic signaling and vascular integrity. 
Developmental cell 15, 272-284. 
Fitch, M.J., Campagnolo, L., Kuhnert, F., and Stuhlmann, H. (2004). Egfl7, a novel epidermal growth 
factor-domain gene expressed in endothelial cells. Dev Dyn 230, 316-324. 
Fleishman, R.A. (1996). Engraftment of W/c-kit mutant mice is determined by stem cell competition, 
not by increased marrow 'space'. Exp Hematol 24, 209-213. 
Fleming, R.J. (1998). Structural conservation of Notch receptors and ligands. Seminars in cell & 
developmental biology 9, 599-607. 
Garbe, A.I., Krueger, A., Gounari, F., Zuniga-Pflucker, J.C., and von Boehmer, H. (2006). Differential 
synergy of Notch and T cell receptor signaling determines alphabeta versus gammadelta lineage fate. 
The Journal of experimental medicine 203, 1579-1590. 
Hassanein, M., Almahayni, M.H., Ahmed, S.O., Gaballa, S., and El Fakih, R. (2016). FLT3 Inhibitors for 
Treating Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 16, 543-549. 
Hattori, K., Heissig, B., Wu, Y., Dias, S., Tejada, R., Ferris, B., Hicklin, D.J., Zhu, Z., Bohlen, P., Witte, L., 
et al. (2002). Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells 
from bone-marrow microenvironment. Nature medicine 8, 841-849. 
Heissig, B., Hattori, K., Dias, S., Friedrich, M., Ferris, B., Hackett, N.R., Crystal, R.G., Besmer, P., Lyden, 
D., Moore, M.A., et al. (2002). Recruitment of stem and progenitor cells from the bone marrow niche 
requires MMP-9 mediated release of kit-ligand. Cell 109, 625-637. 
Heissig, B., Rafii, S., Akiyama, H., Ohki, Y., Sato, Y., Rafael, T., Zhu, Z., Hicklin, D.J., Okumura, K., 
Ogawa, H., et al. (2005). Low-dose irradiation promotes tissue revascularization through VEGF 
release from mast cells and MMP-9-mediated progenitor cell mobilization. The Journal of 
experimental medicine 202, 739-750 Epub 2005 Sep 2012. 
Henry, C.J., Marusyk, A., Zaberezhnyy, V., Adane, B., and DeGregori, J. (2010). Declining lymphoid 
progenitor fitness promotes aging-associated leukemogenesis. Proceedings of the National Academy 
of Sciences of the United States of America 107, 21713-21718. 
Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley, D., Ullman-Cullere, M., Ross, 
F.P., Coller, B.S., Teitelbaum, S., and Hynes, R.O. (1999). Beta3-integrin-deficient mice are a model 
for Glanzmann thrombasthenia showing placental defects and reduced survival. The Journal of 
clinical investigation 103, 229-238. 
Hooper, A.T., Butler, J.M., Nolan, D.J., Kranz, A., Iida, K., Kobayashi, M., Kopp, H.G., Shido, K., Petit, I., 
Yanger, K., et al. (2009). Engraftment and reconstitution of hematopoiesis is dependent on VEGFR2-
mediated regeneration of sinusoidal endothelial cells. Cell stem cell 4, 263-274. 
Huang, E., Nocka, K., Beier, D.R., Chu, T.Y., Buck, J., Lahm, H.W., Wellner, D., Leder, P., and Besmer, P. 
(1990). The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit 
receptor, the gene product of the W locus. Cell 63, 225-233. 
Johnson, L., Huseni, M., Smyczek, T., Lima, A., Yeung, S., Cheng, J.H., Molina, R., Kan, D., De, M., xE, 
et al. (2013). Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF 
efficacy. The Journal of clinical investigation 123, 3997-4009. 
Kanegae, Y., Makimura, M., and Saito, I. (1994). A simple and efficient method for purification of 
infectious recombinant adenovirus. Jpn J Med Sci Biol 47, 157-166. 
Kato, T., Sakata-Yanagimoto, M., Nishikii, H., Ueno, M., Miyake, Y., Yokoyama, Y., Asabe, Y., Kamada, 
Y., Muto, H., Obara, N., et al. (2015). Hes1 suppresses acute myeloid leukemia development through 
FLT3 repression. Leukemia 29, 576-585. 
Kenins, L., Gill Jw Fau - Hollander, G.A., Hollander Ga Fau - Wodnar-Filipowicz, A., and Wodnar-
Filipowicz, A. (2010). Flt3 ligand-receptor interaction is important for maintenance of early thymic 
progenitor numbers in steady-state thymopoiesis. Eur J Immunol 40 (1), 81-90. 
32 
 
Kiel, M.J., and Morrison, S.J. (2006). Maintaining Hematopoietic Stem Cells in the Vascular Niche. 
Immunity 25, 862-864. 
Kobayashi, T., and Kageyama, R. (2010). Hes1 regulates embryonic stem cell differentiation by 
suppressing Notch signaling. Genes to Cells 15, 689-698. 
Kuhnert, F., Mancuso, M.R., Hampton, J., Stankunas, K., Asano, T., Chen, C.Z., and Kuo, C.J. (2008). 
Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. 
Development 135, 3989-3993. 
Kumar, C.C. (2003). Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced 
angiogenesis. Current drug targets 4, 123-131. 
Le Bras, A., Samson, C., Trentini, M., Caetano, B., Lelievre, E., Mattot, V., Beermann, F., and Soncin, F. 
(2010). VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a 
proximal promoter under the direct control of Erg and GATA-2. PloS one 5. 
Lechman, E.R., Gentner, B., van†Galen, P., Giustacchini, A., Saini, M., Boccalatte, F.E., Hiramatsu, H., 
Restuccia, U., Bachi, A., Voisin, V., et al. (2012). Attenuation of miR-126 Activity Expands HSC In†Vivo 
without Exhaustion. Cell stem cell 11, 799-811. 
Li, X., and von Boehmer, H. (2011). Notch Signaling in T-Cell Development and T-ALL. ISRN 
Hematology 2011, 9. 
Li, Z., Chen, P., Su, R., Li, Y., Hu, C., Wang, Y., Arnovitz, S., He, M., Gurbuxani, S., Zuo, Z., et al. (2015). 
Overexpression and knockout of miR-126 both promote leukemogenesis. Blood 126, 2005-2015. 
Li, Z., Lu, J., Sun, M., Mi, S., Zhang, H., Luo, R.T., Chen, P., Wang, Y., Yan, M., Qian, Z., et al. (2008). 
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. 
Proceedings of the National Academy of Sciences of the United States of America 105, 15535-15540. 
Linton, P.J., and Dorshkind, K. (2004). Age-related changes in lymphocyte development and function. 
Nat Immunol 5, 133-139. 
Liu, Z., Wang, F., and Chen, X. (2008). Integrin α(v)β(3)-Targeted Cancer Therapy. Drug development 
research 69, 329-339. 
Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P., and Lemischka, I.R. (1995). 
Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. 
Immunity 3, 147-161. 
Mayer, T.C., and Green, M.C. (1968). An experimental analysis of the pigment defect caused by 
mutations at the W and S1 loci in mice. Developmental biology 18, 62-75. 
Moore, T.A., and Zlotnik, A. (1997). Differential effects of Flk-2/Flt-3 ligand and stem cell factor on 
murine thymic progenitor cells. J Immunol 158, 4187-4192. 
Murphy, M., Reid, K., Williams, D.E., Lyman, S.D., and Bartlett, P.F. (1992). Steel factor is required for 
maintenance, but not differentiation, of melanocyte precursors in the neural crest. Developmental 
biology 153, 396-401. 
Nichol, D., Shawber, C., Fitch, M.J., Bambino, K., Sharma, A., Kitajewski, J., and Stuhlmann, H. (2010). 
Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood 
116, 6133-6143. 
Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A., and Besmer, P. (1989). 
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant 
mice--evidence for an impaired c-kit kinase in mutant mice. Genes &amp; development 3, 816-826. 
Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term lymphohematopoietic 
reconstitution by a single CD34-low/negative hematopoietic stem cell. Science (New York, NY) 273, 
242-245. 
Palomero, T., Lim, W.K., Odom, D.T., Sulis, M.L., Real, P.J., Margolin, A., Barnes, K.C., O'Neil, J., 
Neuberg, D., Weng, A.P., et al. (2006). NOTCH1 directly regulates c-MYC and activates a feed-
forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National 
Academy of Sciences of the United States of America 103, 18261-18266. 
33 
 
Parker, L.H., Schmidt, M., Jin, S.W., Gray, A.M., Beis, D., Pham, T., Frantz, G., Palmieri, S., Hillan, K., 
Stainier, D.Y., et al. (2004). The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube 
formation. Nature 428, 754-758. 
Picuric, S., Friedrich, M., and Oess, S. (2009). Expression and purification of recombinant human 
EGFL7 protein. Protein Expr Purif 68, 1-6. 
Poulos, M.G., Crowley, M.J., Gutkin, M.C., Ramalingam, P., Schachterle, W., Thomas, J.L., Elemento, 
O., and Butler, J.M. (2015). Vascular Platform to Define Hematopoietic Stem Cell Factors and 
Enhance Regenerative Hematopoiesis. Stem Cell Reports 5, 881-894. 
Puissant, A., Fenouille, N., Alexe, G., Pikman, Y., Bassil, C.F., Mehta, S., Du, J., Kazi, J.U., Luciano, F., 
Rönnstrand, L., et al. (2014). SYK Is a Critical Regulator of FLT3 In Acute Myeloid Leukemia. Cancer 
cell 25, 226-242. 
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H.R., and Aguet, M. (1999). 
Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 10, 547-
558. 
Russell, E.S. (1949). Analysis of pleiotropism at the W-locus in the mouse; relationship between the 
effects of W and Wv substitution on hair pigmentation and on erythrocytes. Genetics 34, 708-723. 
Russell, E.S., and Bernstein, S.E. (1968). Proof of whole-cell implant in therapy of W-series anemia. 
Archives of biochemistry and biophysics 125, 594-597. 
Salama, Y., Hattori, K., and Heissig, B. (2017). The angiogenic factor Egfl7 alters thymogenesis by 
activating Flt3 signaling. Biochemical and biophysical research communications. 
Sambandam, A., Maillard, I., Zediak, V.P., Xu, L., Gerstein, R.M., Aster, J.C., Pear, W.S., and 
Bhandoola, A. (2005). Notch signaling controls the generation and differentiation of early T lineage 
progenitors. Nat Immunol 6, 663-670. 
Schmidt, M.H.H., Bicker, F., Nikolic, I., Meister, J., Babuke, T., Picuric, S., Muller-Esterl, W., Plate, K.H., 
and Dikic, I. (2009). Epidermal growth factor-like domain 7 (EGFL7) modulates Notch signalling and 
affects neural stem cell renewal. Nature cell biology 11, 873-880. 
Seguin, L., Kato, S., Franovic, A., Camargo, M.F., Lesperance, J., Elliott, K.C., Yebra, M., Mielgo, A., 
Lowy, A.M., Husain, H., et al. (2014). A β3 integrin-KRAS-RalB complex drives tumor stemness and 
resistance to EGFR inhibition. Nature cell biology 16, 457-468. 
Seita, J., and Weissman, I.L. (2010). Hematopoietic stem cell: self-renewal versus differentiation. 
Wiley interdisciplinary reviews Systems biology and medicine 2, 640-653. 
Shen, Q., Goderie, S.K., Jin, L., Karanth, N., Sun, Y., Abramova, N., Vincent, P., Pumiglia, K., and 
Temple, S. (2004). Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem 
cells. Science (New York, NY) 304, 1338-1340. Epub 2004 Apr 1301. 
Sitnicka, E., Buza-Vidas, N., Ahlenius, H., Cilio, C.M., Gekas, C., Nygren, J.M., Månsson, R., Cheng, M., 
Jensen, C.T., Svensson, M., et al. (2007). Critical role of FLT3 ligand in IL-7 receptor–independent T 
lymphopoiesis and regulation of lymphoid-primed multipotent progenitors. Blood 110, 2955. 
Solanilla, A., Grosset, C., Lemercier, C., Dupouy, M., Mahon, F.X., Schweitzer, K., Reiffers, J., Weksler, 
B., and Ripoche, J. (2000). Expression of Flt3-ligand by the endothelial cell. Leukemia 14, 153-162. 
Soncin, F., Mattot, V., Lionneton, F., Spruyt, N., Lepretre, F., Begue, A., and Stehelin, D. (2003). VE-
statin, an endothelial repressor of smooth muscle cell migration. The EMBO journal 22, 5700-5711. 
Stier, S., Cheng, T., Dombkowski, D., Carlesso, N., and Scadden, D.T. (2002). Notch1 activation 
increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage 
outcome. Blood 99, 2369-2378. 
Umemoto, T., Yamato, M., Shiratsuchi, Y., Terasawa, M., Yang, J., Nishida, K., Kobayashi, Y., and 
Okano, T. (2006). Expression of Integrin β3 Is Correlated to the Properties of Quiescent Hemopoietic 
Stem Cells Possessing the Side Population Phenotype. The Journal of Immunology 177, 7733-7739. 
Wang, S., Aurora, A.B., Johnson, B.A., Qi, X., McAnally, J., Hill, J.A., Richardson, J.A., Bassel-Duby, R., 
and Olson, E.N. (2008). The endothelial-specific microRNA miR-126 governs vascular integrity and 
angiogenesis. Developmental cell 15, 261-271. 
34 
 
Weinberg, K., Blazar, B.R., Wagner, J.E., Agura, E., Hill, B.J., Smogorzewska, M., Koup, R.A., Betts, 
M.R., Collins, R.H., and Douek, D.C. (2001). Factors affecting thymic function after allogeneic 
hematopoietic stem cell transplantation. Blood 97, 1458-1466. 
Yang, R.H., Qi, S.H., Ruan, S.B., Lin, Z.P., Lin, Y., Zhang, F.G., Chen, X.D., and Xie, J.L. (2016). EGFL7-
overexpressing epidermal stem cells promotes fibroblast proliferation and migration via mediating 
cell adhesion and strengthening cytoskeleton. Molecular and cellular biochemistry 423, 1-8. 
Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W.G., Ross, J., Haug, J., Johnson, T., Feng, J.Q., et al. 
(2003). Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 
836-841. 
Zhang, Y., Yang, P., Sun, T., Li, D., Xu, X., Rui, Y., Li, C., Chong, M., Ibrahim, T., Mercatali, L., et al. 
(2013). miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory 
monocytes to inhibit breast cancer metastasis. Nature cell biology 15, 284-294. 
Zsebo, K.M., Williams, D.A., Geissler, E.N., Broudy, V.C., Martin, F.H., Atkins, H.L., Hsu, R.Y., Birkett, 
N.C., Okino, K.H., Murdock, D.C., et al. (1990). Stem cell factor is encoded at the Sl locus of the 
mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63, 213-224. 
 
 
